Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2010Circulation JournalOpen Access

After a 2-week treatment, the mean MPA significantly increased from baseline in both groups with no significant difference between the omeprazole and rabeprazole groups (55.73 ± 19.66% vs 48.46 ± 18.80%; P=0.141).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does omeprazole compared to rabeprazole differentially affect the antiplatelet action of clopidogrel in CAD patients?

Population

87 patients with coronary artery disease (CAD) receiving clopidogrel and aspirin

Comparison

Omeprazole 20 mg once daily for at least 2 weeks vs Rabeprazole 20 mg once daily for at least 2 weeks

Design

RCT, randomized, open-labeled

Follow-up

at least 2 weeks

Authors

SSSuksiri SiriswangvatNSNakarin SansanayudhSNSurakit Nathisuwan

Discussion

Loading...

Member takes

Overview

Both PPIs similarly blunt clopidogrel antiplatelet effect; confirms no differential interaction in CAD patients.

Structured PICO

Does omeprazole compared to rabeprazole differentially affect the antiplatelet action of clopidogrel in CAD patients?

P
Population
87 patients with coronary artery disease (CAD) receiving clopidogrel and aspirin
I
Intervention
Omeprazole 20 mg once daily for at least 2 weeks
C
Comparator
Rabeprazole 20 mg once daily for at least 2 weeks
O
Outcome
Mean maximal platelet aggregation (MPA) induced by Adenosine 5-diphosphate 20 µmol/L before and after PPI treatmentsurrogate

Both omeprazole and rabeprazole similarly decrease the antiplatelet effect of clopidogrel in CAD patients, as measured by ADP-induced platelet aggregation.

Cite This Study

Siriswangvat et al. (2010) studied this question.

synapsesocial.com/papers/6a7d79e8e9ec6b5ffa6e4bedhttps://doi.org/10.1253/circj.cj-09-0913
View Full Paper
Ask AI
Bookmark
Share